Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abionyx Pharma has the Financial Strength Rank of 5.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.
A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Abionyx Pharma did not have earnings to cover the interest expense.
Abionyx Pharma's debt to revenue ratio for the quarter that ended in Dec. 2025 was 0.98.
As of today, Abionyx Pharma's Altman Z-Score is 3.96.
The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Abionyx Pharma has the Financial Strength Rank of 5.
Abionyx Pharma Financial Strength Related Terms
LTS:0RAG vs VRTX, REGN, MRNA: Financial Strength Comparison
For the Biotechnology subindustry, Abionyx Pharma's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abionyx Pharma Financial Strength vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abionyx Pharma's Financial Strength distribution charts can be found below:
* The bar in red indicates where Abionyx Pharma's Financial Strength falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Abionyx Pharma has a Z-score of 3.96, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 3.96 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abionyx Pharma (LTS:0RAG) has a Financial Strength of 5 as of Dec. 2025. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Abionyx Pharma and its competitors. This is near median its historical median of 5.00. Over the past decade, Abionyx Pharma's Financial Strength has ranged from 2.00 to 9.00.
Is Abionyx Pharma's Financial Strength too high?
Abionyx Pharma's current Financial Strength of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 9.00. Overall, Abionyx Pharma has a GF Score™ of 14/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Abionyx Pharma's Financial Strength compare to VRTX and REGN?
Abionyx Pharma's Financial Strength of 5 can be compared against companies in the Biotechnology industry. Historically, Abionyx Pharma's own Financial Strength has ranged from 2.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Biotechnology company?
A good Financial Strength depends on the Biotechnology industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Abionyx Pharma and its competitors. Abionyx Pharma's current Financial Strength is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abionyx Pharma stock overvalued right now?
Based on GuruFocus' analysis, Abionyx Pharma (LTS:0RAG) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.79, compared to a current price of €1.82 — trading 130.6% above its estimated fair value. The current Financial Strength is 5, which is near median its 10-year median of 5.00. Abionyx Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For Abionyx Pharma (LTS:0RAG), the current Financial Strength is 5 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abionyx Pharma (LTS:0RAG) Overvalued in 2026?
Based on GuruFocus' analysis, Abionyx Pharma stock appears to be overvalued.
The current stock price of €1.82 is trading 130.6% above its estimated GF Value™ of €0.79.
GuruFocus considers Abionyx Pharma to be Significantly Overvalued.
Key valuation signals for LTS:0RAG:
Financial Strength: 5 (near median its 10-year median of 5.00)
GF Value™: €0.79 vs. price of €1.82 (130.6% above fair value)
No single metric tells the full story. See the LTS:0RAG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
14GF Score
Get the complete analysis for LTS:0RAG
Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAG has been successfully added to your 
